Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats with Monocrotaline-induced Pulmonary Hypertension

Journal of Cardiovascular Pharmacology

Volumn 65, Issue 6, 2015, Pages 640-648

  Nakata, Telma M ^a   Tanaka, Ryou ^a   Yoshiyuki, Rieko ^a   Fukayama, Toshiharu ^a   Goya, Seijiro ^a   Fukushima, Ryuji ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

ATP sensitive potassium channel; cardiac function; phosphodiesterase inhibitors

Indexed keywords

MONOCROTALINE; NICORANDIL; PIMOBENDAN; SILDENAFIL; SODIUM CHLORIDE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PYRIDAZINE DERIVATIVE; VASODILATOR AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; EXPERIMENTAL HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; MONOCROTALINE-INDUCED PULMONARY HYPERTENSION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; WISTAR RAT;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MONOCROTALINE; NICORANDIL; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 5 INHIBITORS; PYRIDAZINES; RATS, WISTAR; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SILDENAFIL CITRATE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 84934965965     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000236     Document Type: Article

References (79)

1. Galiè N, Torbicki A, Barst R, et al Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243-2278.
2. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54:S85-S96.
3. Gupta H, Ghimire G, Naeije R. The value of tools to assess pulmonary arterial hypertension. Eur Respir Rev. 2011;20:222-235.
4. Lee KS, Abbas AE, Khandheria BK, et al. Echocardiographic assessment of right heart hemodynamic parameters. J Am Soc Echocardiogr. 2007;20:773-782.
5. Vonk Noordegraaf A, Galiè N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2011;20:243-253.
6. Brierre G, Blot-Souletie N, Degano B, et al. New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. Eur J Echocardiogr. 2010;11:516-522.
7. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114:1883-1891.
8. Bogaard HJ, Abe K, Noordegraaf AV, et al. The right ventricle under pressure. Cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135:794-804.
9. Vanderpool RR, Pinsky MR, Naeije R, et al. RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension. Heart. 2014; pii: heartjnl-2014-306142.
10. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120:992-1007.
11. Van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58:2511-2519.
12. Maclean MR, Johnston ED, McCulloch KM, et al. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther. 1997;283:619-624.
13. Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol. 2002;137:1187-1194.
14. Jeffery TK, Wanstall JC. Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension. J Cardiovasc Pharmacol. 1998;32:213-219.
15. Matot I, Gozal Y. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest. 2004;125:644-651.
16. Lobato EB, Beaver T, Muehjschlegel J, et al. Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. Br J Anaesth. 2006;96:317-322.
17. Rabe KF, Tenor H, Dent G, et al. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994;266:L536-L543.
18. Atkinson KJ, Fine DM, Thombs LA, et al. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med. 2009;23:1190-1196.
19. Böhm M, Morano I, Pieske B, et al. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res. 1991;68:689-701.
20. Von Der Leyen H, Mende U, Meyer W, et al. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:90-100.
21. Wilkins MR, Wharton J, Grimminger F, et al. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J. 2008;32:198-209.
22. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248.
23. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222.
24. Fisher PW, Salloum F, Das A, et al. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation. 2005;111:1601-1610.
25. Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiovasc Pharmacol. 1987;10:S1-S9.
26. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology. 2003;99:1415-1432.
27. Li J, Long C, Cui W, et al. Iptakalim ameliorates monocrotaline-induced pulmonary arterial hypertension in rats. J Cardiovasc Pharmacol Ther. 2013;18:60-69.
28. Hongo M, Mawatari E, Sakai A, et al. Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats. J Cardiovasc Pharmacol. 2005;46:452-458.
29. Sahara M, Sata M, Morita T, et al. Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension. PLoS One. 2012;7:e33367.
30. Zuo XR, Wang Q, Cao Q, et al. Nicorandil prevents right ventricular remodeling by inhibiting apoptosis and lowering pressure overload in rats with pulmonary arterial hypertension. PLoS One. 2012;7:e44485.
31. Bardou M, Goirand F, Marchand S, et al. Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition. J Cardiovasc Pharmacol. 2001;38:325-334.
32. Haddad F, Hunt SA, Rosenthal DN, et al. Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008;117:1436-1448.
33. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685-713.
34. Zoghbi WA, Enriquez-Sarano M, Foster E, et al American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777-802.
35. Lindqvist P, Calcutteea A, Henein M. Echocardiography in the assessment of right heart function. Eur J Echocardiogr. 2008;9:225-234.
36. Faul JL, Nishimura T, Berry GJ, et al. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med. 2000;162:2252-2258.
37. Braun MU, Szalai P, Strasser RH, et al. Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes. Cardiovasc Res. 2003;59:658-667.
38. Nishii Y, Gabazza EC, Fujimoto H, et al. Protective role of protein C inhibitor in monocrotaline-induced pulmonary hypertension. J Thromb Haemost. 2006;4:2331-2339.
39. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:615-621.
40. Jones JE, Mendes L, Rudd MA, et al. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol. 2002;283:H364-H371.
41. Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1013-L1032.
42. Gomez-Arroyo JG, Farkas L, Alhussaini AA, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012;302:L363-L369.
43. Ferlinz J. Right ventricular diastolic performance: compliance characteristics with focus on pulmonary hypertension, right ventricular hypertrophy, and calcium channel blockade. Cathet Cardiovasc Diagn. 1998;43:206-243.
44. Haddad F, Doyle R, Murphy DJ, et al. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008;117:1717-1731.
45. Boissiere J, Gautier M, Machet MC, et al. Doppler tissue imaging in assessment of pulmonary hypertension-induced right ventricle dysfunction. Am J Physiol Heart Circ Physiol. 2005;289:H2450-H2455.
46. Hardziyenka M, Campian ME, de Bruin-Bon HA, et al. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr. 2006;19:1272-1279.
47. Koskenvuo JW, Mirsky R, Zhang Y, et al. A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. Int J Cardiovasc Imaging. 2010;26:509-518.
48. Walker LA, Buttrick PM. The right ventricle: biologic insights and response to disease: updated. Curr Cardiol Rev. 2013;9:73-81.
49. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. J Biol Chem. 2005;280:12944-12955.
50. Shan X, Quaile MP, Monk JK, et al. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail. 2012;5:79-86.
51. Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8-17.
52. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
53. Pamboukian SV, Carere RG, Webb JG, et al. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transplant. 1999;18:367-371.
54. Fujino K, Sperelakis N, Solaro RJ. Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res. 1988;63:911-922.
55. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol. 1996;119:609-615.
56. Yoshiyuki R, Nakata TM, Fukayama T, et al. Pimobendan improves right ventricular myocardial contraction and attenuates pulmonary arterial hypertension in rats with monocrotaline-induced pulmonary arterial hypertension. J Med Ultrason. 2014;14:173-180.
57. Tissier R, Chetboul V, Moraillon R, et al. Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy. Cardiovasc Toxicol. 2005;5:43-51.
58. Burniston JG, Ellison GM, Clark WA, et al. Relative toxicity of cardiotonic agents: some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others. Cardiovasc Toxicol. 2005;5:355-364.
59. Chetboul V, Lefebvre HP, Sampedrano CC, et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. J Vet Intern Med. 2007;21:742-753.
60. Walter M, Liebens I, Goethals H, et al. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. Br J Clin Pharmacol. 1988;25:323-329.
61. Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study). Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J. 2002;66:149-157.
62. Watanabe E, Shiga T, Matsuda N, et al. Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension. Cardiovasc Drugs Ther. 2003;17:375-379.
63. Sahara M, Takahashi T, Imai Y, et al. New insights in the treatment strategy for pulmonary arterial hypertension. Cardiovasc Drugs Ther. 2006;20:377-386.
64. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr. 1996;9:838-847.
65. Yeo TC, Dujardin KS, Tei C, et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol. 1998;81:1157-1161.
66. Holzmann S. Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75). J Cardiovasc Pharmacol. 1983;5:364-370.
67. Gori T, Sicuro S, Dragoni S, et al. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation. 2005;111:742-746.
68. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005;127:1647-1653.
69. Ishizuka N, Saito K, Akima M, et al. Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation. Jpn J Pharmacol. 2000;84:316-324.
70. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995;26:1581-1585.
71. Kiely DG, Cargill RI, Wheeldon NM, et al. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res. 1997;33:201-208.
72. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
73. Fan TH, Liang CS, Kawashima S, et al. Alterations in cardiac beta-adrenoceptor responsiveness and adenylate cyclase system by congestive heart failure in dogs. Eur J Pharmacol. 1987;140:123-132.
74. Bristow MR, Minobe W, Rasmussen R, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.
75. Wang GY, McCloskey DT, Turcato S, et al. Contrasting inotropic responses to alpha1-adrenergic receptor stimulation in left versus right ventricular myocardium. Am J Physiol Heart Circ Physiol. 2006;291:H2013-H2017.
76. McClanahan A, Guglin M. Right ventricular dysfunction compromises accuracy of echocardiographic diagnosis of pulmonary hypertension in heart failure. J Card Fail. 2011;17:1023-1027.
77. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167:735-740.
78. Rich S, D'Alonzo GE, Dantzker DR, et al. Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. Am J Cardiol. 1985;55:159-163.
79. Sahay S, Tonelli AR. Pericardial effusion in pulmonary arterial hypertension. Pulm Circ. 2013;3:467-477.